Literature DB >> 23910013

Increased IL-23 and IL-17 expression by peripheral blood cells of patients with primary biliary cirrhosis.

Cheng Qian1, Tingwang Jiang, Weiwei Zhang, Chuanlu Ren, Qianqian Wang, Qin Qin, Jie Chen, Anmei Deng, Renqian Zhong.   

Abstract

Primary biliary cirrhosis (PBC) is a typical autoimmune disease for which the pathogenesis remains unclear. IL-23 and IL-17 are pro-inflammatory cytokines of the "IL-23/IL-17 axis," which may play a key role in the pathogenesis of autoimmune diseases. In this study, we investigated the expression of IL-23 and IL-17 in the peripheral blood of patients with PBC and its clinical significance. We used quantitative PCR to determine mRNA expressions of IL-23, IL-23 receptor, and IL-17 in peripheral blood mononuclear cells (PBMC) from PBC patients. ELISA's were used to determine patients' serum levels of IL-23 and IL-17. IL-23- and IL-17-producing cells in liver biopsis were also analyzed. Compared to a healthy control group, the mRNA expression levels of IL-23 p19, its corresponding receptor, IL-23R, and IL-17 in PBMC's from PBC patients were significantly increased, and these levels were correlated with PBC disease stages. PBC patients' serum levels of IL-23 and IL-17 were higher than those in a post-hepatic cirrhosis group and a healthy group, and were significantly higher in the early PBC disease stages than in the advanced PBC stages. There were significantly more IL23+ and IL-17+ mononuclear cells in portal areas of liver tissues in advanced stages of this disease than in the early stages. The serum levels of IL-23 and IL-17 in PBC patients were positively correlated with serum GGT levels. Thus, IL-23 and IL-17 may play an important role in the pathogenesis of PBC by promoting inflammation. Because the IL-23 and IL-17 levels in the peripheral blood of PBC patients were increased and were correlated with clinical stages, they may be indices that could be used to clinically monitor PBC.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IL-17; IL-23; Primary biliary cirrhosis (PBC)

Mesh:

Substances:

Year:  2013        PMID: 23910013     DOI: 10.1016/j.cyto.2013.07.005

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  25 in total

1.  Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors.

Authors:  Xue-Xiu Zhang; Li-Feng Wang; Lei Jin; Yuan-Yuan Li; Shu-Li Hao; Yan-Chao Shi; Qing-Lei Zeng; Zhi-Wei Li; Zheng Zhang; George Kk Lau; Fu-Sheng Wang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.

Authors:  Oihane Erice; Patricia Munoz-Garrido; Javier Vaquero; Maria J Perugorria; Maite G Fernandez-Barrena; Elena Saez; Alvaro Santos-Laso; Ander Arbelaiz; Raul Jimenez-Agüero; Joaquin Fernandez-Irigoyen; Enrique Santamaria; Verónica Torrano; Arkaitz Carracedo; Meenakshisundaram Ananthanarayanan; Marco Marzioni; Jesus Prieto; Ulrich Beuers; Ronald P Oude Elferink; Nicholas F LaRusso; Luis Bujanda; Jose J G Marin; Jesus M Banales
Journal:  Hepatology       Date:  2018-02-21       Impact factor: 17.425

3.  IL12B and IL23R polymorphisms are associated with alopecia areata.

Authors:  Pardis-Sadat Tabatabaei-Panah; Hamideh Moravvej; Sara Delpasand; Mona Jafari; Sanaz Sepehri; Reyhaneh Abgoon; Ralf J Ludwig; Reza Akbarzadeh
Journal:  Genes Immun       Date:  2020-05-01       Impact factor: 2.676

Review 4.  IL-17 Axis Driven Inflammation in Non-Alcoholic Fatty Liver Disease Progression.

Authors:  Daniel A Giles; Maria E Moreno-Fernandez; Senad Divanovic
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 5.  Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics.

Authors:  Ji-Won Park; Jung-Hee Kim; Sung-Eun Kim; Jang Han Jung; Myoung-Kuk Jang; Sang-Hoon Park; Myung-Seok Lee; Hyoung-Su Kim; Ki Tae Suk; Dong Joon Kim
Journal:  Biomedicines       Date:  2022-05-31

Review 6.  Th17 cells in the liver: balancing autoimmunity and pathogen defense.

Authors:  Nobuhito Taniki; Nobuhiro Nakamoto; Po-Sung Chu; Masataka Ichikawa; Toshiaki Teratani; Takanori Kanai
Journal:  Semin Immunopathol       Date:  2022-02-24       Impact factor: 11.759

7.  IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy.

Authors:  Chen-Yen Yang; Xiong Ma; Koichi Tsuneyama; Shanshan Huang; Toru Takahashi; Naga P Chalasani; Christopher L Bowlus; Guo-Xiang Yang; Patrick S C Leung; Aftab A Ansari; Linda Wu; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2014-04-01       Impact factor: 17.425

8.  The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis.

Authors:  Qiannan Sun; Qian Wang; Ning Feng; Yan Meng; Bin Li; Demei Luo; Xiaoqian Shang; Jie Lv; Ahmad Maqsuod Monsaf; Changmin Wang; Xiumin Ma
Journal:  Ann Transl Med       Date:  2019-08

9.  The role of IL-23/Th17 pathway in patients with primary immune thrombocytopenia.

Authors:  Xin Ye; Lei Zhang; Hui Wang; Yan Chen; Weiwei Zhang; Rongrong Zhu; Chaoping Fang; Anmei Deng; Baohua Qian
Journal:  PLoS One       Date:  2015-01-26       Impact factor: 3.240

10.  Serum cytokine profiling analysis for zheng differentiation in chronic hepatitis B.

Authors:  Yi-Yu Lu; Yu Zhao; Ya-Nan Song; Shu Dong; Bin Wei; Qi-Long Chen; Yi-Yang Hu; Shi-Bing Su
Journal:  Chin Med       Date:  2015-08-27       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.